State Street’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-3,449,457
| Closed | -$14.1M | – | 5022 |
|
|
2022
Q1 | $14.1M | Buy |
3,449,457
+108,267
| +3% | +$393K | ﹤0.01% | 2632 |
|
|
2021
Q4 | $11.9M | Sell |
3,341,190
-122,485
| -4% | -$428K | ﹤0.01% | 2818 |
|
|
2021
Q3 | $12.6M | Buy |
3,463,675
+12,821
| +0.4% | +$51.8K | ﹤0.01% | 2749 |
|
|
2021
Q2 | $15M | Sell |
3,450,854
-1,260,131
| -27% | -$5.13M | ﹤0.01% | 2677 |
|
|
2021
Q1 | $19.4M | Buy |
4,710,985
+627,335
| +15% | +$2.72M | ﹤0.01% | 2387 |
|
|
2020
Q4 | $16.3M | Sell |
4,083,650
-93,171
| -2% | -$301K | ﹤0.01% | 2355 |
|
|
2020
Q3 | $11.3M | Sell |
4,176,821
-404,458
| -9% | -$1.12M | ﹤0.01% | 2376 |
|
|
2020
Q2 | $12.6M | Buy |
4,581,279
+687,912
| +18% | +$1.92M | ﹤0.01% | 2291 |
|
|
2020
Q1 | $9.19M | Sell |
3,893,367
-206,423
| -5% | -$702K | ﹤0.01% | 2329 |
|
|
2019
Q4 | $19.3M | Buy |
4,099,790
+114,825
| +3% | +$470K | ﹤0.01% | 2152 |
|
|
2019
Q3 | $13.3M | Sell |
3,984,965
-109,756
| -3% | -$361K | ﹤0.01% | 2319 |
|
|
2019
Q2 | $13.5M | Buy |
4,094,721
+511,501
| +14% | +$1.48M | ﹤0.01% | 2336 |
|
|
2019
Q1 | $10.9M | Sell |
3,583,220
-548,128
| -13% | -$1.78M | ﹤0.01% | 2426 |
|
|
2018
Q4 | $11.2M | Buy |
4,131,348
+410,048
| +11% | +$1.35M | ﹤0.01% | 2370 |
|
|
2018
Q3 | $12.5M | Buy |
3,721,300
+1,219,238
| +49% | +$3.77M | ﹤0.01% | 2457 |
|
|
2018
Q2 | $6.45M | Sell |
2,502,062
-22,782
| -0.9% | -$56.7K | ﹤0.01% | 2738 |
|
|
2018
Q1 | $5.55M | Buy |
2,524,844
+75,716
| +3% | +$170K | ﹤0.01% | 2751 |
|
|
2017
Q4 | $4.87M | Sell |
2,449,128
-187,728
| -7% | -$409K | ﹤0.01% | 2804 |
|
|
2017
Q3 | $8.54M | Buy |
2,636,856
+609,206
| +30% | +$1.88M | ﹤0.01% | 2518 |
|
|
2017
Q2 | $6.53M | Buy |
2,027,650
+1,954,769
| +2,682% | +$5.54M | ﹤0.01% | 2606 |
|
|
2017
Q1 | $206K | Hold |
72,881
| – | – | ﹤0.01% | 3500 |
|
|
2016
Q4 | $170K | Sell |
72,881
-3,300
| -4% | -$6.28K | ﹤0.01% | 3509 |
|
|
2016
Q3 | $129K | Hold |
76,181
| – | – | ﹤0.01% | 3432 |
|
|
2016
Q2 | $80K | Sell |
76,181
-1,986,008
| -96% | -$1.92M | ﹤0.01% | 3558 |
|
|
2016
Q1 | $1.79M | Sell |
2,062,189
-14,769
| -0.7% | -$14.3K | ﹤0.01% | 3046 |
|
|
2015
Q4 | $2.51M | Sell |
2,076,958
-19,557
| -0.9% | -$27.2K | ﹤0.01% | 2904 |
|
|
2015
Q3 | $3.56M | Buy |
2,096,515
+42,815
| +2% | +$83.9K | ﹤0.01% | 2692 |
|
|
2015
Q2 | $4.27M | Buy |
2,053,700
+144,795
| +8% | +$351K | ﹤0.01% | 2706 |
|
|
2015
Q1 | $5.17M | Buy |
1,908,905
+758
| +0% | +$1.92K | ﹤0.01% | 2550 |
|
|
2014
Q4 | $4.9M | Buy |
1,908,147
+23,244
| +1% | +$52.2K | ﹤0.01% | 2577 |
|
|
2014
Q3 | $3.45M | Sell |
1,884,903
-118,262
| -6% | -$258K | ﹤0.01% | 2743 |
|
|
2014
Q2 | $5.35M | Sell |
2,003,165
-137
| -0% | -$412 | ﹤0.01% | 2555 |
|
|
2014
Q1 | $7.01M | Buy |
2,003,302
+4,619
| +0.2% | +$20.5K | ﹤0.01% | 2382 |
|
|
2013
Q4 | $8.95M | Buy |
1,998,683
+45,324
| +2% | +$185K | ﹤0.01% | 2252 |
|
|
2013
Q3 | $7.93M | Buy |
1,953,359
+76,267
| +4% | +$333K | ﹤0.01% | 2248 |
|
|
2013
Q2 | $7.81M | Buy |
+1,877,092
| New | +$7.25M | ﹤0.01% | 2203 |
|
Other funds holding ATRS
State Street's ATRS Position: Q2 2022 in Review
State Street sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 3,449,457 shares — an estimated $14.1M sold.
State Street first reported a position in ATRS in Q2 2013 and held it in 36 quarters. The position peaked at $19.4M in Q1 2021. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- State Street reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- State Street sold 3,449,457 Antares Pharma, Inc. shares in Q2 2022, an estimated $14.1M.
- State Street first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 36 quarters.
- State Street's Antares Pharma, Inc. position peaked at $19.4M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on State Street's 13F filing for Q2 2022, filed 15 Aug 2022.